First miRNA therapy to treat diabetes by regeneration of pancreatic cells
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
- New Ocrevus Subcutaneous Injection Therapy Shows Promising Results in Multiple Sclerosis Treatmen
- Dutch Man Infected with COVID-19 for 613 Days Dies: Accumulating Over 50 Virus Mutations
The world’s First miRNA therapy to treat diabetes by regeneration of pancreatic cells was born
First miRNA therapy to treat diabetes by regeneration of pancreatic cells. Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd. (KOSDAQ: 89140), has selected its first technology investment target to expand its new biological business.
Nexturn Bio announced that with the strong support of its parent company Nexturn Bioscience Co., Ltd, the company has obtained a 50% stake in RosVivo Therapeutics, Inc., its ultimate investment target. RosVivo Therapeutics, Inc. is a Nevada-based miRNA drug development company that will receive investment from Nexturn Bio.
Since the outbreak of new coronavirus pneumonia, the development of RNA vaccines has attracted much attention, and now RosVivo’s new drug for diabetes RSVI-301 also uses miRNA.
miRNA is composed of 20-24 nucleotides and is called a kind of “small vacuum cleaner” in the body, which can naturally regulate the metabolism of genes and proteins.
Since these miRNA therapies are infused with human-derived genetic material, they are expected to have greater value in terms of stability than traditional mRNA therapies using external genetic material such as viruses.
In particular, it is worth mentioning that the basic research on new drug development miR-10-5p enables researchers to observe the world’s first pancreatic cell regeneration.
Nexturn Bio Inc. and RosVivo Therapeutics, Inc. stated that they will commission the Scientific Advisory Board (SAB) to conduct a comprehensive verification because this is an important precedent for diabetes research.
The consultants will be composed of members from several large hospitals, such as the Stanford University School of Medicine, who will provide professional advice and support throughout the drug development process.
miR-10-5p becomes a key regulator of gastrointestinal dyskinesia and diabetes through the KLF11-KIT pathway
Nexturn Bio Inc. plans to achieve both “innovation” and “marketability” through RosVivo’s new miRNA drugs. The company’s CEO Song Myung-Seok also participated in the search for candidate investment targets when establishing a subsidiary. “RosVivo is Nexturn Bio’s first formal investment. RosVivo’s RSVI-301 will be an innovative opportunity to open a new era of post-mRNA medicine and challenge the complete treatment of diabetes.”
(source:internet, reference only)
Disclaimer of medicaltrend.org
